Metabolism Products

03 ADME Products · Metabolism

Drug metabolism is the enzymatic biotransformation of xenobiotics into more polar, readily excretable metabolites. Cytochrome P450 enzymes account for the majority of Phase I oxidative reactions, while Phase II conjugation pathways — glucuronidation, sulfation, acetylation, and glutathione conjugation — further modify both parent compounds and Phase I metabolites to facilitate elimination.

Our Metabolism portfolio encompasses hepatic and extrahepatic microsomal fractions, recombinant metabolic enzymes, transporter-expressing cell lines, reaction phenotyping kits, inhibition assay systems, and metabolite identification reagents — supporting the complete drug metabolism characterisation workflow from early screening to regulatory-grade studies.

Hepatic Microsomes Recombinant CYPs P450 Inhibition UGT & SULT Enzymes Reaction Phenotyping Metabolite ID S9 Fractions Cytosol
4
Product Categories
Microsomal fractions · Recombinant enzymes · Inhibition kits · Conjugation tools
10+
Species Coverage
Human · Rat · Mouse · Dog · Monkey · Rabbit · Mini-pig · Guinea pig and more
9
Proprietary Brands
Vesitra™ · P450-Metric™ · AccuMetab™ · six specialist kit lines
30+
Recombinant Enzymes
CYP · UGT · SULT · NAT · MAO · FMO · GST isoforms

Drug metabolism serves two principal functions: inactivation of pharmacologically active compounds to terminate their effect, and bioactivation of prodrugs or stable compounds into reactive intermediates that may be associated with toxicity. The liver is the primary site of drug metabolism, with the highest concentrations of cytochrome P450 (CYP) enzymes — particularly CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 — accounting for the biotransformation of the majority of marketed drugs. Extrahepatic metabolism in the intestine, lung, kidney, and brain contributes to the overall clearance and metabolic profile.

Accurate in vitro characterisation of metabolic pathways is essential for predicting in vivo clearance (CLint), identifying reactive metabolite risks, evaluating drug–drug interaction (DDI) potential through CYP inhibition and induction, and assigning the enzymes responsible for a compound's primary metabolic routes (reaction phenotyping). Our portfolio spans all key in vitro metabolism assay formats — from high-throughput microsomal stability screening through to definitive recombinant enzyme kinetics and soft-spot identification by mass spectrometry.

CYP-mediated metabolism accounts for approximately 75% of all drug biotransformation reactions. Early profiling of CYP inhibition, metabolic stability, and reaction phenotyping is essential for prospective DDI risk assessment and for guiding structural optimisation to improve metabolic stability.
Product Scope at a Glance
  • 01
    Hepatic & Extrahepatic Fractions Liver microsomes · S9 fractions · Cytosol · Hepatocytes (fresh & cryopreserved) · Intestinal & renal microsomes — multi-species
  • 02
    Recombinant Metabolic Enzymes Recombinant CYPs (14 isoforms) · UGTs (12 isoforms) · SULTs · NATs · MAOs · FMOs · GSTs — AccuMetab™ series
  • 03
    P450 Inhibition & Induction Kits Direct / time-dependent inhibition assay kits · CYP induction tools · Reaction phenotyping probe substrate panels — P450-Metric™ series
  • 04
    Phase II Conjugation & Specialist Kits UGT activity kits · Sulfation assays · GSH trapping kits · Transporter cell lines · Metabolite stability tools
Drug Metabolism Pathway
I
Phase I — Oxidation
CYP450-mediated hydroxylation, N-dealkylation, O-dealkylation, epoxidation; also FMO, MAO, AO reactions
II
Phase II — Conjugation
Glucuronidation (UGT), sulfation (SULT), acetylation (NAT), methylation (COMT), glutathione conjugation (GST)
RM
Reactive Metabolites
Electrophilic intermediates trapped by GSH, KCN, or semicarbazide; assessed for covalent binding risk
DDI
CYP Inhibition / Induction
Reversible and time-dependent CYP inhibition measured with fluorescent or LC-MS/MS probe substrates
CL
Intrinsic Clearance (CLint)
CLint scaled from microsomal t½ or Vmax/Km to predict in vivo hepatic clearance (CLh)
Section 02
Product Type
Browse Metabolism products by application area and reagent class
Hepatic & Extrahepatic Fractions

Liver microsomes, S9 fractions, cytosol, and hepatocytes are the foundation of in vitro metabolic stability and clearance prediction. Multi-species pools and gender-specific lots enable cross-species scaling and metabolic phenotype characterisation.

Liver Microsomes
  • Human liver microsomes — pooled (mixed gender, 10/50/150 donor)
  • Human liver microsomes — gender-specific donor lots
  • Rat (Sprague-Dawley), mouse (C57BL/6, CD-1), dog (beagle) microsomes
  • Cynomolgus and rhesus monkey liver microsomes
  • Mini-pig (Göttingen), rabbit, guinea pig liver microsomes
S9 Fractions & Cytosol
  • Human liver S9 fraction — pooled (mixed gender)
  • Rat, mouse, dog, cynomolgus monkey S9 fractions
  • Human liver cytosol (AO, XO, SULT, NAT activity)
  • Rat and mouse liver cytosol fractions
  • Lung, kidney, and intestinal S9 fractions (multi-species)
Hepatocytes
  • Cryopreserved human hepatocytes — pooled (5, 10, 20 donor)
  • Platable human hepatocytes (induction-grade)
  • Suspension-format human hepatocytes (CLint screening)
  • Cryopreserved rat, mouse, dog, monkey hepatocytes
  • 3D spheroid hepatocyte culture kits
Cofactors & Assay Reagents
  • NADPH regenerating system (Solution A + B)
  • UDPGA (uridine 5′-diphosphoglucuronic acid)
  • PAPS (3′-phosphoadenosine 5′-phosphosulfate)
  • Acetyl-CoA (for NAT assays)
  • GSH (reduced glutathione) trapping reagent grade
Recombinant Metabolic Enzymes

Recombinant enzymes expressed in baculovirus-insect cell or E. coli systems provide defined, single-enzyme activity for precise reaction phenotyping, kinetic parameter determination (Km, Vmax, CLint), and isothermal stability experiments without interference from co-expressed isoforms.

Recombinant CYP Enzymes
  • CYP1A2, CYP2A6, CYP2B6 (baculosomes + control)
  • CYP2C8, CYP2C9 (R144C, I359L variants available)
  • CYP2C19, CYP2D6 (EM phenotype, PM phenotype)
  • CYP2E1, CYP3A4, CYP3A5, CYP3A7
  • CYP4F2 (warfarin ω-hydroxylase); CYP2J2 (cardiac)
Recombinant UGT Enzymes
  • UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9
  • UGT2B4, UGT2B7 (major drug glucuronidation isoforms)
  • UGT2B10, UGT2B15, UGT2B17
  • Expressed in HEK293 or baculovirus systems
  • Matched HEK293 / insect cell control microsomes
Phase I & II Specialty Enzymes
  • SULT1A1, SULT1A3, SULT2A1 (recombinant)
  • NAT1, NAT2 (N-acetyltransferases)
  • MAO-A, MAO-B (monoamine oxidases)
  • FMO1, FMO3, FMO5 (flavin monooxygenases)
  • GSTA1, GSTP1, GSTM1 (glutathione-S-transferases)
Enzyme Activity Kits & Controls
  • CYP activity panel control compounds (7 isoforms)
  • Recombinant enzyme incubation buffer kits
  • NADPH regenerating system (recombinant enzyme grade)
  • Protein determination reagents (BCA, Bradford)
  • Specific activity reference standards per isoform
P450 Inhibition & DDI Assessment

CYP inhibition — both reversible and mechanism-based (time-dependent) — is a primary driver of clinical drug–drug interactions. In vitro IC50 and Ki determination using probe substrates in human liver microsomes or recombinant enzymes provides the data required for prospective DDI risk assessment and regulatory submissions.

Fluorescent Substrate Kits
  • CYP1A2 / CYP2C19 — CEC fluorescent substrate kit
  • CYP2C9 — MFC fluorescent substrate kit
  • CYP2D6 — AMMC / MAMC fluorescent substrate kit
  • CYP3A4 — BFC / DBF fluorescent substrate kit
  • Multi-CYP cocktail inhibition screening panel
LC-MS/MS Probe Substrate Panels
  • 7-isoform CYP reaction phenotyping probe set
  • CYP2C8 probe (paclitaxel 6α-hydroxylation)
  • CYP2B6 probe (bupropion hydroxylation)
  • CYP3A4/5 midazolam + testosterone dual substrate kit
  • Pooled cassette dosing inhibition panel (n-in-1 format)
Time-Dependent Inhibition (TDI)
  • TDI pre-incubation assay kits (shift assay format)
  • kinact / KI determination kits
  • Mechanism-based inhibitor positive controls (ABT, troleandomycin)
  • Partition ratio determination (catalytic turnover) kits
  • Recombinant CYP3A4 + OR for TDI mechanistic studies
CYP Induction Assessment
  • Platable human hepatocytes (CYP induction grade)
  • PXR / AhR reporter cell assay kits
  • mRNA quantification primer sets (CYP1A2, 2B6, 3A4)
  • Positive induction controls (rifampicin, omeprazole, phenobarbital)
  • Induction culture media and supplement kits
Phase II Conjugation & Reactive Metabolite Tools

Phase II conjugation reactions enhance the polarity of drug molecules and their Phase I metabolites, facilitating renal and biliary excretion. UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) are the dominant Phase II enzymes in drug metabolism, while reactive metabolite trapping assays identify electrophilic intermediates that may pose bioactivation risk.

UGT Activity & Phenotyping Kits
  • UGT reaction phenotyping probe substrate panel (8 isoforms)
  • UDPGA supplemented glucuronidation assay kits
  • Alamethicin pore-forming reagent (microsomal UGT activation)
  • β-Glucuronidase hydrolysis reversal kits
  • UGT1A1 inhibition assay kit (estradiol 3-glucuronidation)
SULT & NAT Assay Kits
  • SULT1A1 activity assay kit (4-nitrophenol sulfation)
  • SULT2A1 activity assay kit (DHEA sulfation)
  • NAT1 and NAT2 phenotyping kits
  • PAPS cofactor supplementation system
  • Cytosolic sulfotransferase inhibitor panel
Reactive Metabolite Trapping
  • GSH trapping assay kits (electrophilic soft metabolites)
  • KCN trapping kits (iminium ion detection)
  • Semicarbazide trapping kits (aldehyde metabolites)
  • Protein covalent binding assay kits (14C / 3H reference)
  • Reactive metabolite positive control panel
Metabolite Identification Reagents
  • Metabolic soft-spot identification assay kits
  • Isotope-labelled internal standard sets (d6-metabolite references)
  • Diclofenac metabolite reference standards (4′-OH, acyl glucuronide)
  • Buspirone metabolite standard panel
  • Metabolite ID reference compound libraries (CYP, UGT, SULT)
Section 03
Search by Brands
Proprietary brands within the Metabolism portfolio
Transporter Cell Lines
Vesitra™
Stably transfected transporter cell lines and membrane vesicle systems for metabolic and efflux DDI characterisation
CYP Inhibition & Phenotyping Kits
P450-Metric™
Fluorescent and LC-MS/MS CYP probe substrate kits for inhibition, TDI, and reaction phenotyping across all major drug-metabolising CYP isoforms
Recombinant Enzymes
AccuMetab™
High-purity, activity-certified recombinant human CYP, UGT, SULT, NAT, MAO, FMO, and GST isoforms for single-enzyme kinetics and phenotyping
Specialist Kit Brands Eight targeted assay kit series covering the full in vitro metabolism workflow
ConjugateIQ™
Phase II Conjugation Kits
UGT and SULT activity assay kits for glucuronidation and sulfation phenotyping, isoform kinetics, and inhibition profiling.
FluxControl™
Transporter Flux Kits
Bidirectional flux assay kits for Vesitra™ cell lines; efflux ratios and inhibitor IC50 for P-gp, BCRP, MRP2, and SLC transporters.
MetaboStat™
Metabolic Stability Kits
High-throughput microsomal and hepatocyte metabolic stability kits for in vitro t½ and CLint determination.
CypMaster™
CYP Phenotyping Kits
Reaction phenotyping kits combining recombinant CYP panels, chemical inhibitor correlation sets, and RAF normalisation.
ConjuLink™
Reactive Metabolite Kits
GSH, KCN, and semicarbazide trapping kits for electrophilic reactive metabolite detection and covalent binding quantification.
MetaVital™
Hepatocyte Culture Kits
Hepatocyte thawing, plating, and culture optimisation kits for induction assays, long-term metabolic studies, and 3D spheroid formation.
CytoFinal™
Incubation Quench Kits
Standardised quench reagents for halting CYP microsomal and hepatocyte incubations; optimised for LC-MS/MS sample preparation.
MetaboStat™ Pro
Extended Stability & Clearance
Advanced kits for extended incubation, low-clearance profiling, non-specific binding correction, and plasma stability screening.
More Brands Coming Soon
Additional kit series are planned as the Metabolism portfolio expands.
Section 04
Products
Full Metabolism product catalogue — filter by category

The product catalogue below is ready to receive SKU data. Use the filter chips to browse by dimension. Each product entry carries a catalogue number, product name, category classification, species applicability, format, and a datasheet link.

For Research Use Only | Not For Clinical Use

Filters

[Cat#: ITS-0426-YL2]

AccuMetab™ Human CYP3A4 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP3A4 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL3]

AccuMetab™ Human CYP2C9 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2C9 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL4]

AccuMetab™ Human CYP2D6 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2D6 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL5]

AccuMetab™ Human CYP2C19 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2C19 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL6]

AccuMetab™ Human CYP1A1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP1A1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL7]

AccuMetab™ Human CYP3A5 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP3A5 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL8]

AccuMetab™ Human CYP2B6 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2B6 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL10]

AccuMetab™ Human CYP4A11 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP4A11 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL11]

AccuMetab™ Human CYP2A13 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2A13 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL12]

AccuMetab™ Human CYP3A7 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP3A7 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL13]

AccuMetab™ Human CYP4F3 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI); Toxicology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP4F3 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL14]

AccuMetab™ Human CYP17A1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Oncology; Endocrinology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP17A1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL15]

AccuMetab™ Human CYP46A1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Neurology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP46A1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL16]

AccuMetab™ Human CYP2E1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Toxicology; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2E1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL17]

AccuMetab™ Human CYP2A6 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Toxicology; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2A6 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL18]

AccuMetab™ Human CYP2C9∗ 2 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2C9∗ 2 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL19]

AccuMetab™ Human CYP2C9∗ 3 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2C9∗ 3 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL20]

AccuMetab™ Human CYP2D6∗ 2 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2D6∗ 2 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL21]

AccuMetab™ Human CYP2D6∗ 10 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2D6∗ 10 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL22]

AccuMetab™ Human CYP2D6∗ 17 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2D6∗ 17 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL23]

AccuMetab™ Human CYP2D6∗ 39 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2D6∗ 39 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL24]

AccuMetab™ Human CYP1B1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Oncology
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP1B1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL25]

AccuMetab™ Human CYP1B1∗ 3 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Oncology; Pharmacogenetics
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP1B1∗ 3 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL26]

AccuMetab™ Human CYP1B1∗ 4 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Oncology; Pharmacogenetics
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP1B1∗ 4 variant for precise pharmacogenetic Phase I profiling.

[Cat#: ITS-0426-YL27]

AccuMetab™ Human CYP2C18 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP2C18 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL29]

AccuMetab™ Human CYP26A1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP26A1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL30]

AccuMetab™ Human CYP26B1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP26B1 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL31]

AccuMetab™ Human CYP51 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Drug-Drug Interactions (DDI)
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Human CYP51 for accurate Phase I drug metabolism profiling.

[Cat#: ITS-0426-YL32]

AccuMetab™ Human NADPH-P450 Reductase, Catalytically Active
Product Type Recombinant Phase I Accessory Enzyme
Research Areas ADME; Assay Development
Species Human
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Essential human reductase for supporting robust Phase I assays.

[Cat#: ITS-0426-YL33]

AccuMetab™ Canine CYP1A1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP1A1 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL34]

AccuMetab™ Canine CYP2B11 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP2B11 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL35]

AccuMetab™ Canine CYP2C21 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP2C21 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL36]

AccuMetab™ Canine CYP2C41 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP2C41 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL37]

AccuMetab™ Canine CYP2D15 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP2D15 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL38]

AccuMetab™ Canine CYP3A12 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP3A12 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL39]

AccuMetab™ Canine CYP3A26 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP3A26 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL40]

AccuMetab™ Canine CYP1A2 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP1A2 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL41]

AccuMetab™ Canine CYP1B1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Veterinary Pharmacology
Species Beagle
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Canine CYP1B1 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL42]

AccuMetab™ Cynomolgus Monkey CYP2C8 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP2C8 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL43]

AccuMetab™ Cynomolgus Monkey CYP2C9 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP2C9 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL44]

AccuMetab™ Cynomolgus Monkey CYP2C19 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP2C19 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL45]

AccuMetab™ Cynomolgus Monkey CYP2C76 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP2C76 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL46]

AccuMetab™ Cynomolgus Monkey CYP3A4 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP3A4 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL47]

AccuMetab™ Cynomolgus Monkey CYP3A5 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Cynomolgus monkey CYP3A5 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL48]

AccuMetab™ Rhesus Monkey CYP1B1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Monkey
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Rhesus monkey CYP1B1 for reliable preclinical Phase I profiling.

[Cat#: ITS-0426-YL49]

AccuMetab™ Mouse CYP2B10 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Mouse
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Mouse CYP2B10 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL50]

AccuMetab™ Mouse CYP3A11 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Mouse
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Mouse CYP3A11 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL51]

AccuMetab™ Mouse CYP1B1 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Mouse
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Mouse CYP1B1 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL52]

AccuMetab™ Pig CYP2C49 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Pig
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Pig CYP2C49 for reliable preclinical Phase I ADME profiling.

[Cat#: ITS-0426-YL53]

AccuMetab™ Pig CYP1A2 Enzyme, Catalytically Active
Product Type Recombinant Phase I Metabolizing Enzyme
Research Areas ADME; Preclinical Toxicology
Species Pig
Brand AccuMetab
Development Stage ADME
ADME Research Domain Metabolism
Short Description Pig CYP1A2 for reliable preclinical Phase I ADME profiling.
Online Inquiry